eli lilly retatrutide press release 2024 2025 is now pharma's top revenue company. It just got FDA approval for an oral GLP-1, but Wall Street isn't celebrating Lilly weight loss drug exceeds

The Endocrine Society's position statement on obesity pharmacotherapy describes weight regain after stopping medication as evidence of ongoing disease activity, not treatment failure

Oral formulations face absorption challenges due to rerouted digestive pathways, reducing bioavailability by 30-50% compared to injections

The transdermal compositions instantly achieve steady state in rats and the concentration is sustained over at least 12 hrs, preferably over 24 hrs

Small amounts of L-carnitine have been given to infants in their breast milk and the formula with no reported side effects

for video podcasts, health tips and uplifting stories designed for women 40, 50, 60 and beyond